Literature DB >> 27756155

Effect of tocolytic drugs on fetal heart rate variability: a systematic review.

Kim M J Verdurmen1, Alexandra D J Hulsenboom1, Judith O E H van Laar1, S Guid Oei1,2.   

Abstract

INTRODUCTION: Tocolytics may cause changes in fetal heart rate (HR) pattern, while fetal heart rate variability (HRV) is an important marker of fetal well-being. We aim to systematically review the literature on how tocolytic drugs affect fetal HRV.
MATERIALS AND METHODS: We searched CENTRAL, PubMed and EMBASE up to June 2016. Studies published in English, using computerized or visual analysis to describe the effect of tocolytics on HRV in human fetuses were included. Studies describing tocolytics during labor, external cephalic version, pre-eclampsia and infection were excluded. Eventually, we included six studies, describing 169 pregnant women.
RESULTS: Nifedipine, atosiban and indomethacin administration show no clinically important effect on fetal HRV. Following administration of magnesium sulfate decreased variability and cases of bradycardia are described. Fenoterol administration results in a slight increase in fetal HR with no changes in variability. After ritodrine administration increased fetal HR and decreased variability is seen. The effect of co-administration of corticosteroids should be taken into account.
CONCLUSION: In order to prevent iatrogenic preterm labor, the effects of tocolytic drugs on fetal HRV should be taken into account when monitoring these fetuses.

Entities:  

Keywords:  Tocolytic therapy; beta-adrenergic agonist; calcium channel blocker; fetal heart rate variability; oxytocin receptor antagonist; prostaglandin antagonist

Mesh:

Substances:

Year:  2016        PMID: 27756155     DOI: 10.1080/14767058.2016.1249844

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  5 in total

1.  Fetal-growth-restricted preterm infants display compromised autonomic cardiovascular control on the first postnatal day but not during infancy.

Authors:  Emily Cohen; Flora Y Wong; Euan M Wallace; Joanne C Mockler; Alexsandria Odoi; Samantha Hollis; Rosemary S C Horne; Stephanie R Yiallourou
Journal:  Pediatr Res       Date:  2017-04-07       Impact factor: 3.756

2.  Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation.

Authors:  Scott D Barnett; Hazik Asif; Mitchell Anderson; Iain L O Buxton
Journal:  J Pharmacol Exp Ther       Date:  2020-12-31       Impact factor: 4.030

3.  In utero exposure to ritodrine during pregnancy and risk of autism in their offspring until 8 years of age.

Authors:  Jungsoo Chae; Geum Joon Cho; Min-Jeong Oh; KeonVin Park; Sung Won Han; Suk-Joo Choi; Soo-Young Oh; Cheong-Rae Roh
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

4.  The electrical heart axis of the fetus between 18 and 24 weeks of gestation: A cohort study.

Authors:  Carlijn Lempersz; Lore Noben; Sally-Ann B Clur; Edwin van den Heuvel; Zhouzhao Zhan; Monique Haak; S Guid Oei; Rik Vullings; Judith O E H van Laar
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

5.  Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.

Authors:  Tsuyoshi Murata; Hyo Kyozuka; Shun Yasuda; Toma Fukuda; Teruyoshi Tanaka; Keiya Fujimori
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.